OVERDOSE
No data are available regarding overdosage in humans.
Should accidental ocular overdosage occur, flush eye(s)
with water or normal saline. If accidentally ingested,
efforts to decrease further absorption may be appropriate
(gastric lavage). The most common signs and symptoms to
be expected with overdosage with administration of a systemic
beta-adrenergic blocking agent are symptomatic bradycardia,
hypotension, bronchospasm, and acute cardiac failure.
Should these symptoms occur, discontinue BETAGAN therapy
and initiate appropriate supportive therapy. The following
supportive measures should be considered:
1. Symptomatic bradycardia: Use atropine
sulfate intravenously in a dosage of 0.25 mg to 2 mg to
induce vagal blockade. If bradycardia persists, intravenous
isoproterenol hydrochloride should be administered cautiously.
In refractory cases the use of a transvenous cardiac pacemaker
should be considered.
2. Hypotension: Use sympathomimetic pressor
drug therapy, such as dopamine, dobutamine, or levarterenol.
In refractory cases the use of glucagon hydrochloride
may be useful.
3. Bronchospasm: Use isoproterenol hydrochloride.
Additional therapy with aminophylline may be considered.
4. Acute cardiac failure: Conventional
therapy with digitalis, diuretics, and oxygen should be
instituted immediately. In refractory cases the use of
intravenous aminophylline is suggested. This may be followed,
if necessary, by glucagon hydrochloride which may be useful.
5. Heart block (second or third degree):
Use isoproterenol hydrochloride or a transvenous cardiac
pacemaker.
CONTRAINDICATIONS
BETAGAN is contraindicated in those individuals with
bronchial asthma, or with a history of bronchial asthma,
or severe chronic obstructive pulmonary disease (see WARNINGS);
sinus bradycardia; second and third degree atrioventricular
block; overt cardiac failure (see WARNINGS); cardiogenic
shock; or hypersensitivity to any component of these products.
|
|
